Reliability and Validity of Visual Assessments of Gait Using a Modified Physician Rating Scale for Crouch and Foot Contact

This study evaluates the visual assessment of gait using portions of the Physicians' Rating Scale (PRS). Thirty children with pathologic gait were evaluated “live” and using full- and slow-speed video. Interobserver reliability (weighted kappa) was 0.57 to 0.74 for foot contact, 0.69 to 0.71 for crouch, 0.30 to 0.40 for hip flexion, 0.57 to 0.65 for knee flexion, and 0.42 to 0.52 for dorsiflexion in stance. Intraobserver reliability (comparing the three conditions) was 0.50 to 0.78 for foot contact, 0.71 to 0.80 for crouch, 0.26 to 0.44 for hip flexion, 0.60 to 0.86 for knee flexion, and 0.39 to 0.61 for dorsiflexion. Observers were correct only 12% to 32% of the time when reporting less than 0 degrees of dorsiflexion and 0% to 29% of the time when reporting more than 20 degrees of hip flexion due to overestimation of hip flexion and underestimation of ankle dorsiflexion. These errors could lead some clinicians to presume the presence of contractures that do not actually exist. Visual assessment using the PRS does not appear to accurately measure what it is most commonly used to assess: ankle position in stance.

[1]  S. Rethlefsen,et al.  Impact of Postoperative Gait Analysis on Orthopaedic Care , 2000, Clinical orthopaedics and related research.

[2]  A. Cosgrove,et al.  Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. , 1998, Journal of pediatric orthopedics.

[3]  S. Rethlefsen,et al.  The Effect of Preoperative Gait Analysis on Orthopaedic Decision Making , 2000, Clinical orthopaedics and related research.

[4]  J. Sławek,et al.  Functional improvement in cerebral palsy patients treated with botulinum toxin A injections – preliminary results , 2003, European journal of neurology.

[5]  L. A. Koman,et al.  Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. , 2001, Pediatrics.

[6]  L. A. Koman,et al.  Management of Cerebral Palsy with Botulinum‐A Toxin: Preliminary Investigation , 1993, Journal of pediatric orthopedics.

[7]  M. Saleh,et al.  In defence of gait analysis. Observation and measurement in gait assessment. , 1985, The Journal of bone and joint surgery. British volume.

[8]  L. A. Koman,et al.  Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. , 2000, Journal of pediatric orthopedics.

[9]  C. Pieper,et al.  Botulinum toxin type a neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. , 2001, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[10]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[11]  T. Wren,et al.  Outcome of gastrocnemius recession and tendo-achilles lengthening in ambulatory children with cerebral palsy , 2004, Journal of pediatric orthopedics. Part B.